<?xml version="1.0" encoding="UTF-8" standalone="no" ?>
<rss version="2.0">
  <channel>
    <title>Kickhoefer, V.A.</title>
    <link>http://repub.eur.nl/res/aut/7172/</link>
    <description>List of Publications</description>
    <language>en</language>
    <image>
      <url>http://repub.eur.nl/static-eur/img/logo.png</url>
      <title>RePub, Erasmus University Rotterdam</title>
      <link>http://repub.eur.nl</link>
    </image>
    <item>
      <title>Disruption of the murine major vault protein (MVP/LRP) gene does not induce hypersensitivity to cytostatics (Article)</title>
      <link>http://repub.eur.nl/res/pub/10037/</link>
      <pubDate>2002-01-01T00:00:00Z</pubDate>
      <description>Vaults are ribonucleoprotein particles with a distinct structure and a
      high degree of conservation between species. Although no function has been
      assigned to the complex yet, there is some evidence for a role of vaults
      in multidrug resistance. To confirm a direct relation between vaults and
      multidrug resistance, and to investigate other possible functions of
      vaults, we have generated a major vault protein (MVP/lung
      resistance-related protein) knockout mouse model. The MVP(-/-) mice are
      viable, healthy, and show no obvious abnormalities. We investigated the
      sensitivity of MVP(-/-) embryonic stem cells and bone marrow cells derived
      from the MVP-deficient mice to various cytostatic agents with different
      mechanisms of action. Neither the MVP(-/-) embryonic stem cells nor the
      MVP(-/-) bone marrow cells showed an increased sensitivity to any of the
      drugs examined, as compared with wild-type cells. Furthermore, the
      activities of the ABC-transporters P-glycoprotein, multidrug
      resistance-associated protein and breast cancer resistance protein were
      unaltered on MVP deletion in these cells. In addition, MVP wild-type and
      deficient mice were treated with the anthracycline doxorubicin. Both
      groups of mice responded similarly to the doxorubicin treatment. Our
      results suggest that MVP/vaults are not directly involved in the
      resistance to cytostatic agents.</description>
    </item>
  </channel>
</rss>